Satellos Bioscience Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MSCLF research report →
Price Chart
About the company
Satellos Bioscience Inc. , a company dedicated to regenerative medicine, focuses on pioneering treatments for various degenerative muscle conditions. A cornerstone of their research is a leading program aimed at developing an orally administered drug.
- CEO
- Francis Gleeson
- IPO
- 2012
- Employees
- 14
- HQ
- Toronto, ON, CA
Get TickerSpark's AI analysis on MSCLF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $96.62M
- P/E
- -1.75
- PEG
- -0.01
- P/S
- 0.00
- P/B
- 0.49
- EV/EBITDA
- -5.09
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -51.42%
- ROIC
- -20.67%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-26,459,000
- Net Income
- $-24,873,000-88419.2%
- EPS
- $-20.40-679900.0%
- OCF Growth
- +5.5%
- FCF Growth
- +5.5%
- 52W High
- $12.50
- 52W Low
- $0.88
- 50D MA
- $7.34
- 200D MA
- $6.08
- Beta
- 0.71
- RSI (14)
- 28
- Avg Volume
- 12.13K
No earnings-call transcripts are available for MSCLF yet.
- Free Float
- 84.4%
- Shares Outstanding
- 15.46M
- Float Shares
- 13.05M
Our MSCLF coverage
Recent articles, reports, and earnings notes.
No research on MSCLF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MSCLF report →Satellos Granted Composition of Matter Patent for Forazapadin
globenewswire.com · Oct 5
Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy
globenewswire.com · Sep 30
Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development
globenewswire.com · Sep 24
Satellos to Present at the 31st Annual Congress of the World Muscle Society
globenewswire.com · Sep 15
Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247
globenewswire.com · Sep 9
Satellos to Participate in Upcoming Investor Conferences
globenewswire.com · Sep 1
Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress
globenewswire.com · Aug 13
Satellos Bioscience DMD Drug Shows Early Promise in 6-Month Study Update
marketbeat.com · Jul 10
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.